Table 1 Correlation between SPTBN1 expression and clinicopathological characteristics in the TCGA ccRCC cohort
Characteristics | Low expression of SPTBN1 | High expression of SPTBN1 | P-Value |
|---|---|---|---|
Total | 269 | 270 | Â |
Age (%) | Â | Â | 0.043 |
  <  = 60 | 122 (22.6%) | 147 (27.3%) |  |
  > 60 | 147 (27.3%) | 123 (22.8%) |  |
Gender (%) | Â | Â | 0.002 |
 Female | 75 (13.9%) | 111 (20.6%) |  |
 Male | 194 (36%) | 159 (29.5%) |  |
Stage (%) |  |  |  < 0.001 |
 Stage I | 102 (19%) | 170 (31.7%) |  |
 Stage II | 32 (6%) | 27 (5%) |  |
 Stage III | 75 (14%) | 48 (9%) |  |
 Stage IV | 58 (10.8%) | 24 (4.5%) |  |
T stage (%) |  |  |  < 0.001 |
 T1 | 106 (19.7%) | 172 (31.9%) |  |
 T2 | 42 (7.8%) | 29 (5.4%) |  |
 T3 | 113 (21%) | 66 (12.2%) |  |
 T4 | 8 (1.5%) | 3 (0.6%) |  |
N stage (%) | Â | Â | 0.124 |
 N0 | 125 (48.6%) | 116 (45.1%) |  |
 N1 | 12 (4.7%) | 4 (1.6%) |  |
M stage (%) |  |  |  < 0.001 |
 M0 | 199 (39.3%) | 229 (45.3%) |  |
 M1 | 55 (10.9%) | 23 (4.5%) |  |